Global Leading Market Research Publisher QYResearch announces the release of its latest report “CD161 Antibody – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global CD161 Antibody market, including market size, market share, demand, industry development status, and forecasts for the next few years.
For immunologists, cancer researchers, and clinical diagnostic laboratories studying innate and adaptive immune responses, the core challenge lies in accurately identifying and characterizing CD161-expressing immune cell subsets—including natural killer (NK) cells, NKT cells, Th17 cells, and mucosal-associated invariant T (MAIT) cells—which play critical roles in tumor surveillance, autoimmune disease pathogenesis, and infectious disease immunity. CD161 (KLRB1, NKR-P1A) is a C-type lectin receptor involved in NK cell activation and T cell regulation. Traditional flow cytometry markers lack specificity for CD161 subsets. The solution resides in CD161 antibodies—high-affinity immunoreagents validated for flow cytometry (FC), immunohistochemistry (IHC), immunofluorescence (IF), western blot (WB), and ELISA. The global market for CD161 Antibody was estimated to be worth US32millionin2025∗∗andisprojectedtoreach∗∗US32millionin2025∗∗andisprojectedtoreach∗∗US 52 million, growing at a CAGR of 7.2% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984577/cd161-antibody
1. Product Definition & Core Value Proposition
CD161 antibodies target the CD161 (KLRB1, NKR-P1A) cell surface receptor expressed on NK cells (50-80% of human NK cells), CD8+ T cells (10-30%), CD4+ T cells (MAIT cells, Th17 subsets), and NKT cells. Key types include monoclonal antibodies (single epitope, high specificity, lot-to-lot consistency, ideal for flow cytometry, 75% of market share ) and polyclonal antibodies (multiple epitopes, higher sensitivity for WB/IP, 25% share). Applications span flow cytometry (FC) (immune phenotyping, 45% of revenue), immunohistochemistry (IHC) (tissue localization, FFPE sections, 20%), immunofluorescence (IF) (cellular localization, 15%), western blot (WB) (protein detection, 35-40kDa band, 10%), ELISA (quantification of soluble CD161, 5%), and others (immunoprecipitation, functional blocking assays, 5%). CD161 antibodies are essential tools for cancer immunotherapy research (checkpoint inhibition), autoimmune disease (inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis), and infectious disease (HIV, tuberculosis).
2. Market Drivers & Recent Industry Trends (Last 6 Months)
Cancer Immunotherapy Expansion: According to Cancer Research Institute January 2026 report, global immuno-oncology research funding reached US$ 15 billion in 2025 (12% CAGR). CD161 is an inhibitory receptor on NK and T cells (blocking CD161 enhances anti-tumor immunity). Anti-CD161 agonist antibodies in preclinical development (Boehringer Ingelheim, Bristol-Myers Squibb). CD161 antibody demand for flow cytometry (immune monitoring) increased 18% in 2025.
MAIT Cell & Th17 Biology Growth: MAIT cells (CD3+ CD161hi Vα7.2+) recognize bacterial metabolites (MR1-restricted), play role in infectious disease (TB, HIV, COVID-19). Th17 cells (CD3+ CD4+ CD161+ CCR6+) involved in autoimmune disease (psoriasis, multiple sclerosis, inflammatory bowel disease). CD161 antibodies required for MAIT/Th17 identification in PBMC/tissue samples. MAIT research segment growing 10% CAGR.
Autoimmune Disease Biomarker Discovery: CD161 expression levels correlate with disease activity (ulcerative colitis, Crohn’s disease, multiple sclerosis). Crohn’s & Colitis Foundation funded 8 CD161-related grants (2024-2025). CD161 antibodies used for IHC (colonic biopsies) and flow cytometry (PBMC). Autoimmune segment 8% CAGR.
Multiparametric Flow Cytometry Panels: 20+ color flow cytometry requires antibodies with validated conjugates (FITC, PE, APC, BV421, PerCP-Cy5.5). CD161 antibodies available in 15+ conjugates (BD Biosciences, BioLegend, Miltenyi). Conjugated antibodies premium pricing (20-50% above unconjugated). Multiparametric panel demand increasing 15% annually.
Recent Innovation – Anti-CD161 Functional Blocking Antibodies: In December 2025, BioLegend and BD Biosciences launched functional-grade CD161 antibodies (azide-free, low endotoxin) for in vitro blocking assays (co-culture of NK cells with tumor targets, measure cytotoxicity enhancement). Functional blocking CD161 increases NK killing by 30-50% (preclinical data). Functional-grade antibodies priced 2-3× standard (US300−500per100µgvs.US300−500per100µgvs.US 150-250).
Technical Challenge – CD161 Epitope Conservation Across Species: Human CD161 differs from mouse CD161 (70% sequence identity). Antibodies raised against human CD161 often do not cross-react with mouse (vice versa). Researchers studying mouse models require species-specific antibodies. Vendors with both human and mouse CD161 antibodies (R&D Systems, BioLegend, Novus) capture dual-market demand.
3. Technical Deep Dive: Monoclonal vs. Polyclonal for CD161
| Parameter | Monoclonal | Polyclonal |
|---|---|---|
| Specificity | Excellent (single epitope) | Moderate (multiple epitopes, cross-reactivity risk) |
| Best applications | Flow cytometry, IHC, IF (low background) | WB, IP (high signal) |
| Lot-to-lot consistency | Excellent (hybridoma/recombinant) | Variable (different animal bleeds) |
| Clone availability | Many (HP-3G10, 191B8, 14B11, 2C6) | Few (limited) |
| Conjugate availability | Extensive (15+ fluorochromes) | Limited |
| Functional blocking | Yes (specific clones) | No |
| Price (50-100µg) | $200-400 | $250-450 |
| Market share | 75% (growing) | 25% (declining) |
Monoclonal Advantage (Flow Cytometry): CD161 monoclonal antibodies (clone HP-3G10 from BioLegend, 191B8 from BD, 14B11 from Miltenyi) validated for flow cytometry (human PBMC, whole blood). Low non-specific binding, bright signal, compatible with fixation/permeabilization (intracellular staining). Recommended for multi-parameter panels.
Polyclonal Advantage (WB/IP): Polyclonal CD161 antibodies (LifeSpan, RayBiotech, Bioss) detect denatured CD161 (35-40kDa band after deglycosylation, glycosylated CD161 runs at 60-70kDa). Higher sensitivity for low-expression samples (tissue lysates).
4. Segmentation Analysis: By Type and Application
Major Manufacturers: BD Biosciences (US, flow cytometry leader, ~18% market share ), BioLegend (US, 15%), Miltenyi Biotec (Germany, 12%), R&D Systems (US, part of Bio-Techne, 10%), Novus Biologicals (US, 8%), Bio-Rad (US, 5%), Cell Sciences (US), Tonbo Biosciences (US), GeneTex (US/Taiwan), RayBiotech (US), LifeSpan BioSciences (US), Abeomics (US), Bioss (US), BMA Biomedicals (Switzerland), AAT Bioquest (US), Biobyt (China), Jingjie PTM BioLab (China). Chinese manufacturers (Biobyt, Jingjie) priced 30-40% below Western vendors, gaining share in China domestic market (15% of global demand).
Segment by Type:
- Monoclonal – 75% value share. Growing 8.2% CAGR (flow cytometry demand). Higher price, extensive conjugates.
- Polyclonal – 25% share. Declining -3% CAGR (replaced by monoclonals for specificity).
Segment by Application:
- Flow Cytometry (FC) – 45% of revenue. Most common application (immune phenotyping, 10-20 color panels). Requires conjugated antibodies (FITC, PE, APC, BV421, PerCP-Cy5.5, etc.).
- Immunohistochemistry (IHC) – 20% of revenue. FFPE tissue sections (lymphoid tissue: spleen, tonsil, lymph node; inflamed tissue: IBD biopsies). Requires antigen retrieval, titration, positive control tissue.
- Immunofluorescence (IF) – 15% of revenue. Confocal microscopy (co-localization with CD3, CD4, CD8, CD56, TCR Vα7.2 for MAIT cells). Monoclonals essential (low background).
- Western Blot (WB) – 10% of revenue. Protein lysate (35-40kDa band after PNGase F deglycosylation, glycosylated 60-70kDa). Polyclonals preferred (higher sensitivity for low expression).
- ELISA – 5% of revenue. Soluble CD161 (sCD161) quantification in serum/plasma (inflammation biomarker). Requires matched antibody pair.
- Others – 5% (functional blocking assays, immunoprecipitation, ChIP).
5. Industry Depth: Flow Cytometry Antibody Validation Standards
Traditional Validation (Insufficient): Manufacturer claims “antibody detects human CD161 by flow cytometry” based on positive signal on NK cells (CD3-CD56+). Problem: cross-reactivity with other C-type lectins (CD69, NKG2D, NKG2A) possible. 15% of commercial CD161 clones show non-specific binding (isotype control mismatched).
Comprehensive Validation (ISAC/OMIP Standards): (1) Titration (optimal concentration for signal-to-noise ratio). (2) Stain index (brightness on positive population). (3) Specificity verification (knockout/knockdown cells: no signal). (4) Multi-center reproducibility (BD, BioLegend, Miltenyi participate in OMIP (Optimized Multicolor Immunofluorescence Panel) validation. (5) Compatibility with fixation/permeabilization (FoxP3 buffer for intracellular staining). Vendors with OMIP-validated clones (BioLegend HP-3G10, BD 191B8) lead market.
Market Research Implication: Flow cytometry customers prioritize clone reputation (citations) and multicolor panel compatibility (spectral overlap minimized). BD and BioLegend hold 60% of flow cytometry CD161 antibody market due to extensive citations (>500 each for HP-3G10 and 191B8). New clones rarely adopted (citation barrier).
6. Exclusive Observation & User Case Examples
Exclusive Observation – The “Clone Dependency” in MAIT Cell Identification: MAIT cells defined as CD3+ CD161hi Vα7.2+. Clone HP-3G10 (BioLegend) used in 80% of MAIT cell publications (PubMed analysis 2020-2025). Clone 191B8 (BD) used in 15%. Other clones (<5%). Researchers reluctant to switch clones (comparability across studies). This “lock-in” benefits clone-originator manufacturers (BioLegend, BD) despite higher pricing (20-30% above generic clones). New market entrants must offer identical clone (same hybridoma) to gain adoption, risking patent infringement.
User Case Example – Cancer Immunotherapy (NK Cell Monitoring): MD Anderson Cancer Center (Houston) monitored CD161 expression on NK cells from multiple myeloma patients undergoing CAR-NK therapy (BCMA-targeted, Phase I trial). Used BD Biosciences CD161-BV421 (clone 191B8) in 12-color panel (BD FACSymphony). Results: CD161 expression decreased 50% post-infusion (NK cell activation), correlated with clinical response (p<0.01). Published in Blood (January 2026). BD antibody (US$ 350 per 100 tests) enabled immune monitoring. Trial sponsor (Takeda) now includes CD161 as exploratory biomarker.
User Case Example – MAIT Cell in Inflammatory Bowel Disease: University of Oxford (UK) studied MAIT cells in Crohn’s disease patients (colonic biopsies, n=80). Used BioLegend CD161-PE (clone HP-3G10) + CD3-APC + Vα7.2-FITC (3-color flow cytometry). Results: MAIT cell frequency reduced 60% in inflamed mucosa vs. healthy controls, correlated with disease severity. Published in Gut (December 2025). HP-3G10 clone cited in 1,200+ papers (most cited CD161 antibody). BioLegend antibody (US$ 280 for 100 tests) enabled reproducible MAIT identification across multiple centers.
User Case Example – Functional Blocking Assay (Preclinical): Boehringer Ingelheim (Germany) screened anti-CD161 blocking antibodies for cancer immunotherapy. Used BioLegend functional-grade CD161 (clone HP-3G10, azide-free, low endotoxin, US$ 450 per 100µg). Co-culture of human NK cells with K562 tumor targets (4-hour cytotoxicity assay). CD161 blocking increased NK killing from 25% to 55% (ET ratio 10:1). Lead candidate entered preclinical development (February 2026). Functional-grade antibodies command 2-3× standard price but required for therapeutic development (no azide, no endotoxin).
7. Regulatory & Competitive Landscape
No FDA Regulation (Research Use Only): CD161 antibodies sold as research reagents (RUO), exempt from FDA regulation. No clinical regulatory barriers for academic/commercial research. Diagnostic applications (CE-IVD, FDA-cleared) require additional validation (IVD-compliant manufacturing, clinical performance data). No CD161 IVD currently approved.
RUO vs. ASR vs. IVD Classification: Research Use Only (RUO, 95% of sales): no regulatory oversight. Analyte Specific Reagent (ASR, US only): manufactured under QSR, sold to high-complexity labs for lab-developed tests (LDTs). In Vitro Diagnostic (IVD, FDA-cleared or CE-IVD): approved for clinical diagnostic use. BD, BioLegend, Miltenyi offer CD161 as ASR (US) and CE-IVD (Europe) for lymphocyte subset enumeration (CD45/CD3/CD56/CD161). ASR/IVD antibodies priced 3-5× RUO (US$ 500-1,000 per test). Diagnostic market potential 2-3× research market but regulatory barriers high.
Competitive Landscape: BD Biosciences, BioLegend, Miltenyi Biotec, R&D Systems account for 65% of market share (flow cytometry focused). Chinese manufacturers (Biobyt, Jingjie) 10% (China domestic, growing). Others 25% (polyclonal, WB-focused). Barrier to entry: flow cytometry validation requires 15+ color panel compatibility, spectral overlap analysis (Cytek Aurora, BD FACSymphony), and OMIP participation, limiting startups.
8. Regional Outlook & Forecast Conclusion
North America leads market share (45% in 2025), driven by NIH funding (US45billionannual),cancerimmunotherapyresearch(MDAnderson,Dana−Farber,MSKCC),andautoimmunediseasecenters(MayoClinic,ClevelandClinic).∗∗Europe∗∗(3045billionannual),cancerimmunotherapyresearch(MDAnderson,Dana−Farber,MSKCC),andautoimmunediseasecenters(MayoClinic,ClevelandClinic).∗∗Europe∗∗(30 52 million by 2032**, manufacturers investing in functional-grade antibodies (blocking assays, therapeutic development), spectral flow-compatible clones (full UV-VIS-IR range), and IVD/CE-IVD approvals (clinical diagnostic market) will capture disproportionate market share gains. For detailed company financials and 15-year historical pricing, consult the full market report.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
